J&J will have to pair up with another DAA to make it appeal to the US customers once Gilead's combo is released. They could moderate the price but most people in the US will want the best Meds. The third world markets and other countries offer a lot more marketing opportunities with a lower price.
It feels like Gilead's Sovaldi will have to make some kind of adjustment in their price with all the attention they are getting from the Federal and State agencies. I suspect that when their new combo gets approved that it will be the new $1,000 pill and Sovaldi will be reduced or somehow discounted via special programs.
These pressures from all sides will make Gilead both squirm and profitable.
matt
OldenSlow said
Mar 21, 2014
Tig,
I'd like to believe in more egalitarian business models. J&J knows they can't sustain the current Olysio price much longer. They'll be looking at more than one set of tail lights. I suspect they will strive to maximize profit while they can.
wayne
Tig said
Mar 20, 2014
Hi Wayne,
That's an interesting article. I see Olysio is going to have quite an uphill battle against Sovaldi for market share. I believe they could regain some ground by lowering their introductory costs and improve their customer relations. It won't be long and Ledispavir will be available and all JnJ will see is Gilead's tail lights!
Tig
OldenSlow said
Mar 20, 2014
From the Decision Resources Group March 19, 2014
"Cost is the leading prescribing barrier for both Olysio and Sovaldi. Although most surveyed prescribers did not indicate major payer obstacles, many non-prescribers reported experiencing reimbursement obstacles, suggesting that reimbursement is a barrier to prescribing."
Hey Wayne & Tig
J&J will have to pair up with another DAA to make it appeal to the US customers once Gilead's combo is released. They could moderate the price but most people in the US will want the best Meds. The third world markets and other countries offer a lot more marketing opportunities with a lower price.
It feels like Gilead's Sovaldi will have to make some kind of adjustment in their price with all the attention they are getting from the Federal and State agencies. I suspect that when their new combo gets approved that it will be the new $1,000 pill and Sovaldi will be reduced or somehow discounted via special programs.
These pressures from all sides will make Gilead both squirm and profitable.
matt
Tig,
I'd like to believe in more egalitarian business models. J&J knows they can't sustain the current Olysio price much longer. They'll be looking at more than one set of tail lights. I suspect they will strive to maximize profit while they can.
wayne
Hi Wayne,
That's an interesting article. I see Olysio is going to have quite an uphill battle against Sovaldi for market share. I believe they could regain some ground by lowering their introductory costs and improve their customer relations. It won't be long and Ledispavir will be available and all JnJ will see is Gilead's tail lights!
Tig
From the Decision Resources Group March 19, 2014
"Cost is the leading prescribing barrier for both Olysio and Sovaldi. Although most surveyed prescribers did not indicate major payer obstacles, many non-prescribers reported experiencing reimbursement obstacles, suggesting that reimbursement is a barrier to prescribing."
Article:
http://hepatitiscnewdrugs.blogspot.com/2014/03/hepatitis-c-sovaldi-based-regimens-will.html
-- Edited by OldenSlow on Thursday 20th of March 2014 07:42:13 PM